
|Videos|December 3, 2021
Dr. Morgans on prostate cancer: “There are so many advances”
Author(s)Urology Times staff
“There are so many advances in prostate cancer, many of which are actually targeted,” says Alicia K. Morgans, MD, MPH.
Advertisement
In this video, Alicia K. Morgans, MD, MPH, discusses the key points of her presentation, “Advanced disease: incorporating molecular markers and genomic studies into therapy,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Morgans is a genitourinary medical oncologist and medical director of the Survivorship Program at the Dana-Farber Cancer Institute in Boston, Massachusetts.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












